AT8704 - A Study of AT13387 in patients with Prostate Cancer

• Research type

  Research Study

• Full title

  A Study of HSP90 Inhibitor AT13387 Alone or in Combination with Abiraterone Acetate in the Treatment of Castration-Resistant Prostate Cancer (CRPC) no Longer Responding to Abiraterone

• IRAS ID

  109119

• Contact name

  Johann de Bono

• Sponsor organisation

  Astex Pharmaceuticals Inc

• Eudract number

  2012-001574-28

• ISRCTN Number

  n/a

• Research summary

  This study is divided in to 2 parts. The first part is a phase 1 study assessing safety and tolerability (incidence and severity of adverse events) of the combination of AT13387 and Abiraterone Acetate and to select the most promising treatment regimen for the combination in subjects with castration-resistant prostate cancer (CRPC) who are no longer responding to treatment with abiraterone acetate alone, based on the overall assessment of safety and antitumor activity. The second part is a phase 2 study, to assess and compare the antitumor activity between single-agent AT13387 and the combination of AT13387 plus abiraterone acetate in subjects who are no longer responding to treatment with abiraterone acetate alone.

• REC name

  London - Surrey Borders Research Ethics Committee

• REC reference

  12/LO/1188

• Date of REC Opinion

  9 Oct 2012

• REC opinion

  Further Information Favourable Opinion